Results 11 to 20 of about 46,143 (249)
Thrombotic thrombocytopenic purpura [PDF]
Nature Reviews Disease Primers, 2017 Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic anaemia and a variable degree of ischaemic organ damage, particularly affecting the brain, heart and kidneys.
Kremer Hovinga, Johanna A. +5 more
semanticscholar +8 more sources
Hereditary thrombotic thrombocytopenic purpura
Haematologica, 2019 The first description of thrombotic thrombocytopenic purpura (TTP) by Moschowitz was published nearly 100 years ago.[1][1] This was likely to have been an immune-mediated TTP episode and the author described multi organs affected with worsening, untreated disease.
Marie Scully
doaj +9 more sources
Vaccination and Thrombotic Thrombocytopenic Purpura
Turkish Journal of Hematology, 2020 In the adult age group, vaccines did not contribute to the development of immune thrombocytopenia (ITP), but an increase was reported in diphtheria-tetanus-pertussis-poliomyelitis vaccines without statistical significance [2].
I. Yavaşoğlu
openaire +5 more sources
Thrombotic Thrombocytopenic Purpura
Journal of Associated Medical Sciences, 2015 -
Nuchanat Nonsee, Prasit Chanarat
doaj +4 more sources
Thrombotic thrombocytopenic purpura [PDF]
memo - Magazine of European Medical Oncology, 2018 Thrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation.
Yaakov Beilin, Joshua Hamburger
openaire +5 more sources
British Journal of Haematology, 2023 The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement ...
M. Scully +12 more
semanticscholar +1 more source
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
Journal of Clinical Medicine, 2021 Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi.
S. Sukumar, B. Lämmle, S. Cataland
semanticscholar +1 more source
Thrombotic Thrombocytopenic Purpura After Ad6.COV2.S Vaccination
Cureus, 2022 Thrombotic thrombocytopenic purpura (TTP) is caused by the deficiency of ADAMTS13, a von Willebrand factor cleaving protease, which results in thrombotic microangiopathy.
S. Ramanan +5 more
semanticscholar +1 more source
Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura.
New England Journal of Medicine, 2022 A 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 deficiency when she presented with an acute episode in ...
L. Asmis +9 more
semanticscholar +1 more source
Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy. [PDF]
Int J Rheum DisThis study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)‐associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.
Ohkubo N +7 more
europepmc +2 more sources